Eli Lilly (NYSE: LLY), the developer of Mounjaro, has proven that it can compete with Novo Nordisk at a high level. Moreover, the company's sibling treatment to Mounjaro -- Zepbound -- has gotten ...

Rosie O'Donnell, who's been opening up about her weight-loss journey online, celebrated her progress in a new post.

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

In the marketing effort promoting Lilly’s Mounjaro, Stonestreet and his mother, Jamey, discuss living with type 2 diabetes and taking the GLP-1 for treatment.

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

INDIANAPOLIS — Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker.

LONDON, Dec 13 (Reuters) - Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker ...

Eli Lilly has followed a similar template to that of Novo Nordisk. Mounjaro is Lilly's response to Ozempic, and is used in treating diabetes. Last year was Mounjaro's first full calendar year on ...

During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting inventory of Zepbound and Mounjaro. Wholesalers purchase medicines from manufacturers and sell them to ...